13 November, 2017
ISRAEL’S FLAGSHIP global giant, Teva Pharmaceuticals, is in deep trouble. Teva’s share price was cut in more than a half. The latest collapse was in part the result of a misguided $40 billion acquisition that left Teva with massive debt and the patent expiration of Copaxone, a drug for treating multiple sclerosis that, at its peak, brought Teva $4 billion in annual revenue and half of the company’s total profit. TEVA One of Israel's largest companies was founded before the establishment of the State of Israel and its importance to Israel is great. Summary Ways to Save TEVA.
